NCCN Flash Update: NCCN Guidelines for Non-Hodgkin's Lymphomas Updated
Flash Update Sent November 30, 2010
NCCN has published updates to the NCCN Guidelines™ for Non-Hodgkin’s Lymphomas. These NCCN Guidelines are currently available as Version 1.2011.
Significant updates include:
- For chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), guidelines for CLL with and without a deletion of 11q and the corresponding suggested treatment regimens were added.
- For follicular lymphoma, the category designation for first-line therapy with bendamustine + rituximab was changed from a category 2A to a category 1. In addition, the category designation for first-line consolidation or extended dosing with rituximab maintenance was changed from a category 2B to a category 1, and “up to 2 y” was added as a qualifier.
- For mycosis fungoides/Sézary syndrome with evidence of folliculotropic or large cell transformation, systemic chemotherapy regimens were added.
- New guidelines were developed for Extranodal NK/T-cell Lymphoma, nasal type and Post-transplant Lymphoproliferative Disorders, and a Principles of Radiation Therapy section was added.
For the complete updated version of these and all NCCN Guidelines, visit NCCN.org.